Efficacy and safety of tarenflurbil, a selective a beta 42-lowering agent, in Alzheimer's disease (AD): A phase 2 trial of up to 24 months of treatment

Efficacy and safety of tarenflurbil, a selective a beta 42-lowering agent, in Alzheimer's disease (AD): A phase 2 trial of up to 24 months of treatment

Dettagli Bibliografici
Autori principali:	Black, S, Wilcock, G, Zavitz, K, Hendrix, S, Swabb, E
Natura:	Conference item
Pubblicazione:	2008

Documenti analoghi

Efficacy and safety of tarenflurbil (flurizan), a selective Abeta42-lowering agent, in Alzheimer's disease (AD): A phase 2 trial of up to 24 months of treatment
di: Wilcock, G, et al.
Pubblicazione: (2007)

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
di: Wilcock, G, et al.
Pubblicazione: (2008)

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.
di: Green, R, et al.
Pubblicazione: (2009)

Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective ab42-lowering agent, in mild Alzheimer's disease (AD): Results of a 12-month Phase 2 trial and 1-year follow-on study
di: Black, S, et al.
Pubblicazione: (2006)

Flurizan, (MPC-7869, (R)-flurbiprofen) a selective A beta-42 lowering agent in patients with mild to moderate Alzheimer's disease: A randomised, placebo-controlled, double blind trial
di: Wilcock, G, et al.
Pubblicazione: (2005)

Efficacy and safety of MPC-7869 (R-flurbiprofen), a Selective AB42-Lowering Agent, in Alzheimer's disease (AD): Results of a 12-month phase 2 trial and 1-year follow-on study.
di: Laughlin, M, et al.
Pubblicazione: (2006)

Variability of A beta removal after A beta 42 immunization in Alzheimer's disease
di: Boche, D, et al.
Pubblicazione: (2007)

MRI Characterizes the Progressive Course of AD and Predicts Conversion to Alzheimer’s Dementia 24 Months Before Probable Diagnosis
di: Christian Salvatore, et al.
Pubblicazione: (2018-05-01)

Changes in alpha- and beta-secretase in Alzheimer's disease
di: Tyler, S, et al.
Pubblicazione: (2003)

A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease
di: Van Leuven Fred, et al.
Pubblicazione: (2005-10-01)

Patients with Alzheimer’s disease have an increased removal rate of soluble beta-amyloid-42
di: Dmitry V. Zaretsky, et al.
Pubblicazione: (2022-01-01)

alpha- and beta-secretase: profound changes in Alzheimer's disease.
di: Tyler, S, et al.
Pubblicazione: (2002)

Noncanonical regulation of imprinted gene Igf2 by amyloid-beta 1–42 in Alzheimer’s disease
di: Emre Fertan, et al.
Pubblicazione: (2023-02-01)

Editorial Vol. 24 Núm. 42
di: Mauricio Sanabria
Pubblicazione: (2022-08-01)

APOE epsilon 4 favours vascular over parenchymal deposition of A beta protein in Alzheimer's disease
di: Chalmers, K, et al.
Pubblicazione: (2002)

Molecular simulation between amyloid beta (1-42), a Peptide associated with alzheimer disease, and zinc(ii) ion
di: Abdul Ghani, Nur Syafiqah
Pubblicazione: (2016)

Association Plasma Aβ42 Levels with Alzheimer’s Disease and Its Influencing Factors in Chinese Elderly Population
di: Wu Y, et al.
Pubblicazione: (2022-08-01)

Cognitive reserve and Aβ1-42 in mild cognitive impairment (Argentina-Alzheimer’s Disease Neuroimaging Initiative)
di: Harris P, et al.
Pubblicazione: (2015-10-01)

Tyramine and Amyloid Beta 42: A Toxic Synergy
di: Sudip Dhakal, et al.
Pubblicazione: (2020-05-01)

Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity.
di: Nicholas J Izzo, et al.
Pubblicazione: (2014-01-01)

Lower CSF Amyloid-Beta<sub>1–42</sub> Predicts a Higher Mortality Rate in Frontotemporal Dementia
di: Daniela Vieira, et al.
Pubblicazione: (2019-10-01)

In silico study of traditional Chinese medicinal compounds targeting alzheimer's disease amyloid beta-peptide (1–42)
di: V. Naveen Kumar, et al.
Pubblicazione: (2023-12-01)

Normal beta-NGF content in Alzheimer's disease cerebral cortex and hippocampus.
di: Allen, S, et al.
Pubblicazione: (1991)

Did Peter Go to Rome in AD 42?
di: John Wenham
Pubblicazione: (1972-05-01)

APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein.
di: Chalmers, K, et al.
Pubblicazione: (2003)

CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer’s Disease and Frontotemporal Dementias
di: Vasilios C. Constantinides, et al.
Pubblicazione: (2023-02-01)

A beta 40 and A beta 42 Amyloid Fibrils Exhibit Distinct Molecular Recycling Properties
di: Sanchez, L, et al.
Pubblicazione: (2011)

Utility of an improved model of amyloid-beta (Aβ<sub>1-42</sub>) toxicity in <it>Caenorhabditis elegans</it> for drug screening for Alzheimer’s disease
di: McColl Gawain, et al.
Pubblicazione: (2012-11-01)

Indomethacin-loaded lipid-core nanocapsules reduce the damage triggered by A&beta;1-42 in Alzheimer&rsquo;s disease models
di: Bernardi A, et al.
Pubblicazione: (2012-09-01)

High-frequency (50 Hz) electroacupuncture ameliorates cognitive impairment in rats with amyloid beta 1–42-induced Alzheimer's disease
di: Chao-Chao Yu, et al.
Pubblicazione: (2018-01-01)

Comparison of the amyloid pore forming properties of rat and human Alzheimer’s beta-amyloid peptide 1-42: Calcium imaging data
di: Coralie Di Scala, et al.
Pubblicazione: (2016-03-01)

Decoding Conformational Imprint of Convoluted Molecular Interactions Between Prenylflavonoids and Aggregated Amyloid-Beta42 Peptide Causing Alzheimer’s Disease
di: E. Srinivasan, et al.
Pubblicazione: (2021-12-01)

Decreased Deposition of Beta-Amyloid 1-38 and Increased Deposition of Beta-Amyloid 1-42 in Brain Tissue of Presenilin-1 E280A Familial Alzheimer’s Disease Patients
di: Felix Dinkel, et al.
Pubblicazione: (2020-07-01)

Father–child interactions at 3 months and 24 months: contributions to children's cognitive development at 24 months
di: Sethna, V, et al.
Pubblicazione: (2017)

Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer’s disease
di: Zhang YY, et al.
Pubblicazione: (2013-01-01)

Cholinesterase inhibitor treatment increases phosphotau accumulation in Alzheimer's disease but reduces A beta in dementia with Lewy bodies
di: Chalmers, K, et al.
Pubblicazione: (2008)

APOE promoter, ACE1 and CYP46 polymorphisms and beta-amyloid in Alzheimer's disease.
di: Chalmers, K, et al.
Pubblicazione: (2004)

Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients
di: Sessa Edoardo, et al.
Pubblicazione: (2011-04-01)

Site-specific structural order in Alzheimer's Aβ42 fibrils
di: Hongsu Wang, et al.
Pubblicazione: (2018-01-01)

Novel neuroprotective function of apical-basal polarity gene crumbs in amyloid beta 42 (aβ42) mediated neurodegeneration.
di: Andrew M Steffensmeier, et al.
Pubblicazione: (2013-01-01)